News Release

Strategic Capital and Business Alliance with Orient EuroPharma Co., Ltd.

Tokyo, Japan - September 17, 2026 - Nano Holdings, Inc. (the "Company") hereby announces that it has signed a memorandum of understanding with Orient EuroPharma Co., Ltd. ("OEP"), a Taiwan-based corporate group engaged in a broad range of healthcare businesses primarily across the Asia-Pacific region, to form a strategic capital and business alliance in the healthcare sector.

This alliance builds on the two companies' long-standing collaboration and mutual trust, dating back to the time of NanoCarrier Co., Ltd. ("NanoCarrier"), the Company's predecessor. By combining the Company's newly established investment business with OEP's business platform, the alliance will broaden a relationship previously centered on drug discovery and advance the creation of new businesses across a wider range of healthcare fields.

1. Background of the Alliance

The relationship between the Company and OEP began in September 2008, when NanoCarrier entered into a license and co-development agreement with OEP concerning the development pipeline for NC-6004, a DDS-based anticancer drug. The companies subsequently continued to collaborate in pharmaceutical development and other areas, including jointly establishing OP NanoPharma Co., Ltd., an injectable drug contract development and manufacturing organization (CDMO), in Taiwan. Through these specific business initiatives, the companies built a relationship of trust over many years. OEP also held shares in NanoCarrier, establishing ties at the capital level as well.

Founded in 1982, OEP is a Taiwanese corporate group with more than 40 years of experience in the healthcare business. It has integrated capabilities spanning pharmaceutical research and development, clinical development, manufacturing, sales and commercialization, and has expanded into health and nutrition products, cosmetics and skincare, medical devices and other fields. With more than 1,000 employees worldwide and 11 overseas subsidiaries, OEP has established a business platform centered on Taiwan and extending across the United States and the Asia-Pacific region. In recent years, OEP has further broadened its business activities through investments in AI healthcare technology companies.

Meanwhile, the Company has undertaken a major transformation of its business model and now operates an investment business focused on identifying promising technologies and businesses, primarily in the healthcare sector. By assigning experienced management professionals to portfolio companies, connecting them with global markets through its domestic and international networks, and taking an active role in their management, the Company accelerates their commercialization and growth.

OEP previously sold its entire shareholding in NanoCarrier. OEP has now recognized the value and future potential of the Company's newly established investment business and has decided to invest in the Company again. OEP's renewed shareholding in the Company reflects its recognition of the Company's investment business and further strengthens the relationship between the two companies. Building on their long-standing trust, the companies will deepen their cooperation at both the business and capital levels and leverage their respective management professionals, domestic and international networks, and business platforms to create and grow new businesses.

2. Future Development under the Alliance

Through the alliance, the companies will combine the Company's capabilities in deal sourcing and evaluation, business development, fundraising, and global networking with OEP's capabilities in investment, research and development, manufacturing, sales, and commercialization, as well as its business platform in the Asia-Pacific region. Through this collaboration, the companies will support market entry in Japan and global expansion for AI healthcare technology companies in which OEP has invested, while further strengthening the Company's capabilities across the investment process, from deal sourcing through the commercialization and growth of portfolio companies.

By leveraging their complementary strengths, the Company and OEP aim to connect promising technologies from Japan, Taiwan and other countries and regions with global markets and create new business opportunities in the healthcare sector.

3. Overview of Orient EuroPharma Co., Ltd.

Company name	Orient EuroPharma Co., Ltd.
Location	Taipei, Taiwan
Representative	President Peter Tsai
Established	June 16, 1982
Business activities	Manufacture and sale of pharmaceuticals, health and nutrition products, cosmetics and other products
Capital	NT$867 million

In connection with the alliance, the Company has resolved to issue new shares through a third-party allotment to Cyntec Co., Ltd., a wholly owned subsidiary of OEP, as the proposed allottee. For details, please refer to the "Notice Regarding Issuance of New Shares through Third-Party Allotment" released today.

Investor and Media Contact
Nano Holdings, Inc.
Corporate Communication
https://www.nano-hd.com/en